Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

2015 Full Year Financial Results

Genmab will report its 2015 full year financial results after market close on February 17. An investor conference call to discuss the results will be held at 6:00 PM CET / 12:00 PM EST on February 17. To join the call by phone, dial one of the following numbers and ask for the Genmab conference call: +45 32 71 16 60 in Denmark, +44 20 3427 1911 in the UK or +1 646 254 3367 in the US. Click here to listen to the webcast. 

Genmab's InvestorPortal

To register your email address for electronic shareholder communications, update how you wish to receive shareholder information from Genmab or register for future AGMs, log on to Genmab's InvestorPortal.

Our Technologies Explained

Learn about Genmab’s proprietary cutting edge technologies, the DuoBody® and HexaBody® platforms at our new technology website